TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

SINGULAIR

MONTELUKAST SODIUM
Neurology Approved 1998-02-20
9
Indications
--
Phase 3 Trials
28
Years on Market

Details

Status
Prescription
First Approved
1998-02-20
Routes
ORAL
Dosage Forms
TABLET, GRANULE, TABLET, CHEWABLE

Companies

Active Ingredient: MONTELUKAST SODIUM

SINGULAIR Approval History

Loading approval history...

What SINGULAIR Treats

3 indications

SINGULAIR is approved for 3 conditions since its original approval in 1998. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Asthma
  • Exercise-Induced Bronchoconstriction
  • Allergic Rhinitis
Source: FDA Label

SINGULAIR Boxed Warning

SERIOUS NEUROPSYCHIATRIC EVENTS Serious neuropsychiatric (NP) events have been reported with the use of SINGULAIR. The types of events reported were highly variable, and included, but were not limited to, agitation, aggression, depression, sleep disturbances, suicidal thoughts and behavior (including suicide). The mechanisms underlying NP events associated with SINGULAIR use are currently not well understood [see Warnings and Precautions (5.1) ] . Because of the risk of NP events, the benefits o...

Drugs Similar to SINGULAIR

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE
BETAMETHASONE ACETATE
2 shared
Hikma
Shared indications:
AsthmaAllergic Rhinitis
CELESTONE SOLUSPAN
BETAMETHASONE ACETATE
2 shared
Merck
Shared indications:
AsthmaAllergic Rhinitis
DEXAMETHASONE
DEXAMETHASONE
2 shared
ALVOGEN
Shared indications:
AsthmaAllergic Rhinitis
DEXAMETHASONE INTENSOL
DEXAMETHASONE
2 shared
Hikma
Shared indications:
AsthmaAllergic Rhinitis
DEXYCU KIT
DEXAMETHASONE
2 shared
EYEPOINT PHARMS
Shared indications:
AsthmaAllergic Rhinitis
KENALOG-40
TRIAMCINOLONE ACETONIDE
2 shared
APOTHECON
Shared indications:
AsthmaAllergic Rhinitis
PEDIAPRED
PREDNISOLONE SODIUM PHOSPHATE
2 shared
SETON PHARM
Shared indications:
Allergic RhinitisAsthma
ACCOLATE
ZAFIRLUKAST
1 shared
STRIDES PHARMA INTL
Shared indications:
Asthma
ADVAIR HFA
FLUTICASONE PROPIONATE
1 shared
GSK
Shared indications:
Asthma
AIRDUO RESPICLICK
FLUTICASONE PROPIONATE
1 shared
Teva
Shared indications:
Asthma
AIRSUPRA
ALBUTEROL SULFATE
1 shared
AstraZeneca
Shared indications:
Asthma
ALVESCO
CICLESONIDE
1 shared
COVIS
Shared indications:
Asthma
ARNUITY ELLIPTA
FLUTICASONE FUROATE
1 shared
GSK
Shared indications:
Asthma
ASMANEX HFA
MOMETASONE FUROATE
1 shared
Merck
Shared indications:
Asthma
BECLOMETHASONE DIPROPIONATE
BECLOMETHASONE DIPROPIONATE
1 shared
AMNEAL IRELAND LTD
Shared indications:
Asthma
BREO ELLIPTA
FLUTICASONE FUROATE
1 shared
GSK
Shared indications:
Asthma
BREYNA
BUDESONIDE
1 shared
Viatris
Shared indications:
Asthma
CARBINOXAMINE MALEATE
CARBINOXAMINE MALEATE
1 shared
MIKART
Shared indications:
Allergic Rhinitis
CINQAIR
RESLIZUMAB
1 shared
Teva
Shared indications:
Asthma
DEPO-MEDROL
METHYLPREDNISOLONE ACETATE
1 shared
Pfizer
Shared indications:
Asthma
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

SINGULAIR FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

SINGULAIR is a leukotriene receptor antagonist indicated for: Prophylaxis and chronic treatment of asthma in patients 12 months of age and older . Acute prevention of exercise-induced bronchoconstriction (EIB) in patients 6 years of age and older . Relief of symptoms of allergic rhinitis (AR): seasonal allergic rhinitis (SAR) in patients 2 years of age and older, and perennial allergic rhinitis (PAR) in patients 6 months of age and older. Reserve use for patients who have an inadequate response or intolerance to alternative therapies . Limitations of Use: Not indicated to treat an acute asthma...

⚠️ BOXED WARNING

WARNING: SERIOUS NEUROPSYCHIATRIC EVENTS Serious neuropsychiatric (NP) events have been reported with the use of SINGULAIR. The types of events reported were highly variable, and included, but were not limited to, agitation, aggression, depression, sleep disturbances, suicidal thoughts and behavior ...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.